Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06843317 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
A Phase 1 study of RSV Infection, sponsored by Clover Biopharmaceuticals USA.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 5
- Study locations
NCT06843317: Recruiting Phase 1 study of RSV Infection, sponsored by Clover Biopharmaceuticals USA.
NCT06843317 is a Phase 1 study of RSV Infection that is actively recruiting participants, run by Clover Biopharmaceuticals USA. The registered enrollment target is 160 participants, below the 727-participant average among 8 other RSV Infection trials with a reported enrollment target (78% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06843317, a Phase 1 study of RSV Infection, is actively recruiting participants, sponsored by Clover Biopharmaceuticals USA.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 5
- Study locations
Study Summary
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
Primary Outcome
Proportion of participants with local and systemic solicited AEs
Conditions Studied
Interventions
- BIOLOGICAL Candidate vaccine, SCB-1019T
- BIOLOGICAL AREXVY
- OTHER placebo
Study Locations (5)
Arizona
- AMR Phoenix - Phoenix
Florida
- AMR Fort Myers - Fort Myers
Kentucky
- AMR Lexington - Lexington
Missouri
- AMR Kansas City - Kansas City
Tennessee
- Knoxville - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2026-06-03 |
| Phase | Phase 1 |
What NCT06843317 shows while recruiting
NCT06843317 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 8 other RSV Infection trials with a reported enrollment target (78% lower).
The record links to 1 condition, with RSV Infection appearing as the primary indexed condition, and to 3 interventions - of which Candidate vaccine, SCB-1019T is the first listed.
NCT06843317 lists 5 locations in 5 states (Arizona, Florida, Kentucky).
Frequently Asked Questions
What is clinical trial NCT06843317 about?
NCT06843317 is a clinical study titled "Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults". CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
What is the current status of trial NCT06843317?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2025-03-21. Estimated completion is 2026-06-03.
What conditions does trial NCT06843317 study?
This clinical trial studies the following conditions: RSV Infection.
What interventions are being tested in trial NCT06843317?
The interventions under investigation include: Candidate vaccine, SCB-1019T (BIOLOGICAL), AREXVY (BIOLOGICAL), placebo (OTHER).
Who is sponsoring clinical trial NCT06843317?
This trial is sponsored by Clover Biopharmaceuticals USA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06843317 being conducted?
This trial has 5 study locations across Arizona, Florida, Kentucky, Missouri, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RSV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06843317's enrollment target sits among peer trials
160 5th of 8 higher than 4 of 8 other RSV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other RSV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
COMPLETED · Phase 1
-
A Study of EDP-323 in Healthy Subjects
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
COMPLETED · Phase 1
-
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
RECRUITING · Phase 3
-
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
RECRUITING
-
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI